ECSP993021A - THERAPEUTIC COMBINATIONS FOR MUSCULOSKELETAL FRAGILITY - Google Patents

THERAPEUTIC COMBINATIONS FOR MUSCULOSKELETAL FRAGILITY

Info

Publication number
ECSP993021A
ECSP993021A ECSP993021A ECSP993021A EC SP993021 A ECSP993021 A EC SP993021A EC SP993021 A ECSP993021 A EC SP993021A EC SP993021 A ECSP993021 A EC SP993021A
Authority
EC
Ecuador
Prior art keywords
compositions
fragility
pyridin
oxo
phenyl
Prior art date
Application number
Other languages
Spanish (es)
Inventor
Hua Zhu Ke
David Duane Thompson
Lydia Codetta Pan
Mei Li
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to ECSP993021 priority Critical patent/ECSP993021A/en
Publication of ECSP993021A publication Critical patent/ECSP993021A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Esta invención se refiere a composiciones farmacéuticas de combinación y a procedimientos que comprenden (-) -cis-6-fenil-5-(4-(2-pirrolidin-1-il-etoxi)-fenil-5,6,7,8-tetrahidronaftalen-2-ol, o una sal farmacéuticamente aceptables del mismo y 2-amino-N-(1(R)-(2,4-difluoro-benciloximetil)2-oxo-2-(3-oxo-3a(R) - piridin - 2-ilmetil)-2-(2,2,2 -trifluoro-etil)-2,3,3a,4,6,7, -hexahidro-pirazolo (4,3 -C(piridin -5-il)-etil)2-metil- propionamida o una sal farmacéuticamente aceptable de la misma, a procedimientos de uso de tales composiciones y a estuches que contiene tales composiciones. Las composiciones son útiles para el tratamiento de la fragilidad musculoesquelética; incluyendo la osteoporosis, fracturas osteoporóticas, reducción de masa ósea, fragilidad y reducción de masa muscular.This invention relates to combination pharmaceutical compositions and processes comprising (-) -cis-6-phenyl-5- (4- (2-pyrrolidin-1-yl-ethoxy) -phenyl-5,6,7,8- tetrahydronaphthalen-2-ol, or a pharmaceutically acceptable salt thereof and 2-amino-N- (1 (R) - (2,4-difluoro-benzyloxymethyl) 2-oxo-2- (3-oxo-3a (R) - pyridin-2-ylmethyl) -2- (2,2,2 -trifluoro-ethyl) -2,3,3a, 4,6,7, -hexahydro-pyrazolo (4,3 -C (pyridin -5-yl ) -ethyl) 2-methyl-propionamide or a pharmaceutically acceptable salt thereof, to methods of using such compositions and to kits containing such compositions The compositions are useful for the treatment of musculoskeletal fragility, including osteoporosis, osteoporotic fractures , reduction of bone mass, fragility and reduction of muscle mass.

ECSP993021 1999-06-16 1999-06-16 THERAPEUTIC COMBINATIONS FOR MUSCULOSKELETAL FRAGILITY ECSP993021A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ECSP993021 ECSP993021A (en) 1999-06-16 1999-06-16 THERAPEUTIC COMBINATIONS FOR MUSCULOSKELETAL FRAGILITY

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ECSP993021 ECSP993021A (en) 1999-06-16 1999-06-16 THERAPEUTIC COMBINATIONS FOR MUSCULOSKELETAL FRAGILITY

Publications (1)

Publication Number Publication Date
ECSP993021A true ECSP993021A (en) 1999-08-12

Family

ID=42044010

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP993021 ECSP993021A (en) 1999-06-16 1999-06-16 THERAPEUTIC COMBINATIONS FOR MUSCULOSKELETAL FRAGILITY

Country Status (1)

Country Link
EC (1) ECSP993021A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11723902B2 (en) 2014-09-04 2023-08-15 Helsinn Healthcare Sa Medical treatments based on anamorelin

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11723902B2 (en) 2014-09-04 2023-08-15 Helsinn Healthcare Sa Medical treatments based on anamorelin

Similar Documents

Publication Publication Date Title
DE60037836D1 (en) ThiazoloÄ4,5-diphyrimidine compounds for the treatment of rheumatoid arthritis
PT991653E (en) NEW COMPOUNDS
CA2400217A1 (en) Pteridine compounds for the treatment of psoriasis
WO2003048164A3 (en) Adenosine a2a receptor antagonists
SI1546127T1 (en) Novel pyrimidineamide derivatives and the use thereof
UY25557A1 (en) THERAPEUTIC COMBINATIONS FOR MUSCULOSKELETAL FRAGILITY
SE0101322D0 (en) Novel compounds
MXPA03000439A (en) Novel form of (r)-n-[5- methyl-8-(4- methylpiperazin-1-yl) -1, 2, 3, 4-tetrahydro -2-naphthyl] -4-morpholinobenzamide.
AR018869A1 (en) PHARMACEUTICAL COMPOSITION, ITS USE FOR THE PREPARATION OF MEDICINES AND CASE THAT CONTAINS IT
ECSP993021A (en) THERAPEUTIC COMBINATIONS FOR MUSCULOSKELETAL FRAGILITY
PL368040A1 (en) Substituted 4-aminocyclohexanol derivatives
WO2002076930A3 (en) Substituted diarylureas as stimulators for fas-mediated apoptosis
ECSP993020A (en) COMBINATION THERAPY FOR MUSCULOSKELETAL FRAGILITY
SE0100296D0 (en) New compounds
SE0100295D0 (en) New compounds
HUP0103544A2 (en) Pharmaceutical composition containing (r)-3-n,n-dicyklobutylamino-8-fluoro-3,4-dihydro-2h-1-benzopyran-5-carboxamide hidrogen-(2r,3r)tartarate monohydrate and paroxetin and process for its preparation